Studysummary This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.
Read the full study on mdpi.com →
Research cited in this study 18
- A Phase 2a Study Investigating the Effects of Ritlecitinib on Brainstem Auditory Evoked Potentials and Intraepidermal Nerve Fiber Histology in Adults with Alopecia Areata Pharmacology Research & Perspectives · 2024
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study Dermatology and therapy · 2023
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth With Ritlecitinib Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study Journal of the American Academy of Dermatology · 2023
- Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment Among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study Journal of the American Academy of Dermatology · 2023
- Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
- Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
- Epidemiological Trends in Alopecia Areata at the Global, Regional, and National Levels Frontiers in immunology · 2022
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata Drug Design Development and Therapy · 2022
- Alopecia Areata: Current Understanding and Management Journal der Deutschen Dermatologischen Gesellschaft · 2022
- Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology · 2021
- A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
- Treatments for Alopecia Areata: A Systematic Review and Network Meta-Analysis Dermatologic therapy · 2021
- Novel Therapies for Alopecia Areata: The Era of Rational Drug Development The Journal of Allergy and Clinical Immunology · 2017
- Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
- Alopecia Areata: An Update Indian Journal of Dermatology, Venereology and Leprology · 2013
- Alopecia Areata: A New Treatment Plan Clinical, cosmetic and investigational dermatology · 2011